INDP Stock Price, Indaptus Therapeutics, . Quote, Chart

Market Summary

USD2.31-0.09

Market Closed

-3.75%

INDP Stock Price

View Fullscreen

INDP RSI Chart

INDP Valuation

Market Cap

19.7M

Price/Earnings (Trailing)

-1.32

EV/EBITDA

-0.57

Price/Free Cashflow

-1.59

MarketCap/EBT

-1.26

INDP Price/Sales (Trailing)

INDP Profitability

Return on Equity

-159.93%

Return on Assets

-136.73%

Free Cashflow Yield

-62.76%

INDP Fundamentals

INDP Earnings

Earnings (TTM)

-15.0M

Earnings Growth (Yr)

10.66%

Earnings Growth (Qtr)

5.07%

Breaking Down INDP Revenue

Last 7 days

7.4%

Last 30 days

-13.2%

Last 90 days

41.7%

How does INDP drawdown profile look like?

INDP Financial Health

Current Ratio

6.7

INDP Investor Care

Shares Dilution (1Y)

1.64%

Diluted EPS (TTM)

-1.78

Tracking the Latest Insider Buys and Sells of Indaptus Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 14, 2023	anderson glen r.	bought	56,005	2.34	23,934	-
Aug 11, 2023	anderson glen r.	bought	74,335	2.12	35,064	-
Aug 10, 2023	anderson glen r.	bought	86,046	1.94	44,354	-
Dec 01, 2022	litchev boyan vesselinov	bought	935	1.8709	500	chief medical officer
Nov 22, 2022	litchev boyan vesselinov	bought	915	1.83	500	chief medical officer
Nov 21, 2022	meckler jeffrey a	bought	18,240	1.9	9,600	ceo and director
Nov 18, 2022	meckler jeffrey a	bought	705	1.7637	400	ceo and director
Sep 08, 2022	meckler jeffrey a	bought	28,862	2.8	10,308	ceo and director
Sep 07, 2022	meckler jeffrey a	bought	22,184	2.57	8,632	ceo and director
Sep 07, 2022	linscott walt addison	bought	393	2.62	150	chief business officer

Which funds bought or sold INDP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	reduced	-32.87	-5,183	29,284	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	426	1,981	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-5.00	-	-%
May 15, 2024	Vivaldi Capital Management LP	unchanged	-	11,563	51,600	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-13.42	843	9,108	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-29,237	-	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	-	2.00	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	25,746	122,699	-%
May 13, 2024	UBS Group AG	reduced	-47.66	-2,173	4,337	-%

Are Funds Buying or Selling INDP?

Are funds buying INDP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INDP

No. of Funds

Recent SEC filings of Indaptus Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Mar 25, 2024	8-K	Current Report
Mar 13, 2024	8-K	Current Report
Mar 13, 2024	424B5	Prospectus Filed
Mar 13, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report

Peers (Alternatives to Indaptus Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Indaptus Therapeutics, Inc. News

Latest updates

Indaptus Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-26.6%	11.00	15.00	18.00	21.00	23.00	28.00	30.00	34.00	37.00	41.00	44.00	20.00	17.00	2.00	21.00
Current Assets	-26.5%	10.00	14.00	17.00	20.00	22.00	27.00	30.00	33.00	37.00	40.00	44.00	19.00	12.00	2.00	14.00
Cash Equivalents	-27.1%	10.00	13.00	16.00	13.00	7.00	10.00	7.00	14.00	33.00	39.00	42.00	17.00	10.00	2.00	9.00
Net PPE	-100.0%	-	735*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	1.00	0.00	3.00
Liabilities	-44.2%	2.00	3.00	2.00	2.00	2.00	3.00	3.00	4.00	4.00	5.00	-	6.00	6.00	2.00	10.00
Current Liabilities	-44.6%	2.00	3.00	2.00	2.00	2.00	3.00	3.00	4.00	4.00	5.00	6.00	5.00	5.00	2.00	8.00
Shareholder's Equity	-22.5%	9.00	12.00	15.00	19.00	21.00	25.00	28.00	30.00	33.00	36.00	38.00	14.00	11.00	15.00	3.00
Retained Earnings	-8.4%	-49.22	-45.42	-41.40	-37.49	-34.20	-29.99	-26.30	-22.90	-19.04	-15.67	-12.45	-215	-207	-7.96	-189
Additional Paid-In Capital	1.9%	58.00	57.00	57.00	56.00	55.00	54.00	54.00	53.00	52.00	51.00	50.00	228	218	8.00	200
Shares Outstanding	1.6%	9.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	3.00	2.00	2.00	2.00	-
Float	-	-	-	-	13.00	-	-	-	15.00	-	-	-	26.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-51.3%	-3,936	-2,601	-3,703	-2,137	-4,962	-2,210	-4,601	-3,148	-3,117	-3,539	-5,630	-1,294	-825	-957	4,449	-1,670	-5,147	-
Share Based Compensation	3.9%	775	746	765	728	727	638	584	904	831	674	795	21.00	20.00	23.00	-739	414	442	-
Cashflow From Investing	-	-	-	7,000	8,000	2,141	5,120	-2,939	-15,809	-2,798	452	-1.65	-1.20	-1.00	-	-	-	769	-
Cashflow From Financing	-	316	-	-	-	-	-	-	-	-	363	42,524	1,775	3,675	-3.96	-9,436	4,491	6,113	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INDP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,591,142	$ 1,879,900
General and administrative	2,352,097	2,575,266
Total operating expenses	3,943,239	4,455,166
Loss from operations	(3,943,239)	(4,455,166)
Other income, net	136,562	201,928
Net loss	$ (3,806,677)	$ (4,253,238)
Net loss available to common stockholders per share of common stock, basic	$ (0.45)	$ (0.51)
Net loss available to common stockholders per share of common stock, diluted	$ (0.45)	$ (0.51)
Weighted average number of shares used in calculating net loss per share, basic	8,442,364	8,401,047
Weighted average number of shares used in calculating net loss per share, diluted	8,442,364	8,401,047
Other comprehensive income:
Reclassification adjustment for interest earned on marketable securities included in net loss		$ (129,229)
Change in unrealized gain on marketable securities		210,252
Comprehensive loss	$ (3,806,677)	$ (4,172,215)

INDP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,741,638	$ 13,362,053
Prepaid expenses and other current assets	551,031	633,156
Total current assets	10,292,669	13,995,209
Non-current assets:
Property and equipment, net		735
Right-of-use asset	151,118	173,206
Other assets	504,728	754,728
Total non-current assets	655,846	928,669
Total assets	10,948,515	14,923,878
Current liabilities:
Accounts payable and other current liabilities	1,434,828	2,672,327
Operating lease liability, current portion	102,464	101,705
Total current liabilities	1,537,292	2,774,032
Non-current liabilities:
Operating lease liability, net of current portion	50,664	73,348
Total non-current liabilities	50,664	73,348
Total liabilities	1,587,956	2,847,380
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 8,538,883 shares issued and outstanding as of March 31, 2024 and 8,401,047 shares issued and outstanding as of December 31, 2023	85,389	84,011
Additional paid in capital	58,499,003	57,409,643
Accumulated deficit	(49,223,833)	(45,417,156)
Total stockholders’ equity	9,360,559	12,076,498
Total liabilities and stockholders’ equity	$ 10,948,515	$ 14,923,878

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

CEO	Mr. Jeffrey A. Meckler
WEBSITE	https://indaptusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Indaptus Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Indaptus Therapeutics, Inc.? What does INDP stand for in stocks?

INDP is the stock ticker symbol of Indaptus Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Indaptus Therapeutics, Inc. (INDP)?

As of Fri May 17 2024, market cap of Indaptus Therapeutics, Inc. is 19.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INDP stock?

You can check INDP's fair value in chart for subscribers.

What is the fair value of INDP stock?

You can check INDP's fair value in chart for subscribers. The fair value of Indaptus Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Indaptus Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INDP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Indaptus Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether INDP is over valued or under valued. Whether Indaptus Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Indaptus Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INDP.